Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2025-12-25 @ 2:11 AM
NCT ID:
NCT07064460
Eligibility Criteria:
MAIN COHORT
INCLUSION CRITERIA:
* A participant may be entered into the study if the participant has at least one of the following: An aneurysm with a maximum diameter of \> 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e, perpendicular to the centerline) measurements; Aneurysm with a history of growth \> 0.5 cm in 6 months; Saccular aneurysm deemed at significant risk for rupture; Symptomatic aneurysm; Ruptured aneurysm
AND
* Extent of aorta to be treated: juxtarenal, pararenal that include 1 or 2 renal and/or accessory renal arteries, paravisceral that includes celiac artery and/or superior mesenteric artery, and/or thoracoabdominal
* High risk of morbidity and mortality with open surgical repair as defined by:
a. Anatomic Criteria (Previous abdominal surgery; Previous thoracotomy; Previous aortic surgery) b. Physiologic Criteria (ASA Category III or higher; Age \>70 years; Previous myocardial infarction, coronary artery disease, or coronary artery stent; Coronary stress test with a reversible perfusion defect; Congestive heart failure (CHF); Chronic obstructive pulmonary disease (COPD))
* Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
* Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a minimum neck length of 25 mm (Diameter in the range of 18 mm - 42 mm; Angle less than 60o relative to the axis of the aneurysm; Angle less than 60o relative to the axis of the suprarenal aorta);
* Minimum branch vessel diameter greater than 5 mm
* Iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 9 mm - 21 mm (for use of ZFEN)
* Contralateral iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 7.5 mm - 20 mm.
* Age: ≥ 18 years old
* Life expectancy: \> 2 years
EXCLUSION CRITERIA:
GENERAL EXCLUSION CRITERIA:
* Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis
* Unwilling to comply with the follow-up schedule
* Inability or refusal to give informed consent by subject or legal representative
* Pregnant or breastfeeding
* Prefers to receive treatment at another hospital with access to a non-physician modified endovascular prosthesis
* Refusal of blood transfusions for religious or personal reasons
* Participation in another investigational clinical or device trial, with the exception of another investigational endovascular stent-graft protocol or percutaneous aortic valve protocol, not encompassed by the IDE protocol and performed remotely from the fenestrated procedure (\> 30 days). Examples include remote (\>30 days) participation in a thoracic, abdominal or iliac branch device trial, or participation in a percutaneous aortic valve trial.
* Mycotic aneurysm or evidence of active systemic infection
MEDICAL EXCLUSION CRITERIA:
* Known sensitivities or allergies to the materials of construction of the devices, including nitinol (nickel, titanium), polyester, polypropylene, gold, stainless steel, and/or solder (tin, silver).
* Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
* Uncorrectable coagulopathy
* Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
• Morbid obesity (BMI ≥ 40 or BMI 30-39.9 with comorbidities)
* Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \< 30 days of the endovascular repair
* Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
* Baseline creatinine greater than 2.0 mg/dL
* History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
* Deemed a high risk due to significant comorbidities, adjudicated by severity according to the Society for Vascular Surgery reporting standards for endovascular aortic repair involving the renal-mesenteric arteries
ANATOMICAL EXCLUSION CRITERIA:
* Thrombus or excessive calcification within the neck of the aneurysm
* Presence of significant thrombus and/or excessive calcification within the intended proximal or distal seal zone of the aneurysm.
* Branch stenosis \> 75% (if left untreated)
* Anatomy that would not allow maintenance of at least one patent hypogastric artery
* Inadequate femoral or iliac access to accommodate the required delivery systems.
* Requirement for iliac conduit in cases of inadequate femoral/iliac access
* Absence of a suitable non-aneurysmal segment of distal thoracic aorta and significant aortic tortuosity.
* Target vessel anatomy not compatible with fenestrated or branched stent graft incorporation, including vessels with severe stenosis, tortuosity and/or insufficient size to accommodate stent graft placement.
* Early target vessel bifurcation precluding safe or effective stent graft placement.
* Unsuitable iliac artery fixation site and/or anatomy for iliac limb extension or iliac branch device placement, as defined by the device instructions for use
Note: Patients with life-threatening aortic disease who have no acceptable surgical or endovascular alternatives will be allowed to receive treatment under this IDE in the non-statistical cohort
Non-statistical Cohort
This cohort will include patients who meet the inclusion criteria and meet any of the above exclusion criteria\* with the exception of the following:
* Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis
* Subject prefers to receive treatment at another hospital with access to a custom-made endovascular prosthesis
* Refusal to give informed consent by the subject or legal representative. Note: Inability to consent prior to surgery will not be exclusionary if it is for life-saving measures.
* Known sensitivities or allergies to the materials of construction of the devices will be allowed in a life-threatening situation where the patient would not survive open surgery.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07064460
Study Brief:
Protocol Section:
NCT07064460